FierceBiotech 4. Feb. 2026 Lilly drops 3 pipeline drugs, including gene therapy, from $1B Prevail buyout
FierceBiotech 4. Feb. 2026 Medtronic steps up with up to $585M deal for Israeli devicemaker CathWorks
FierceBiotech 4. Feb. 2026 Hims & Hers to sell Grail’s Galleri multi-cancer blood test via its digital health platform
FierceBiotech 4. Feb. 2026 NHS 'FIT' bowel cancer test reduced unnecessary referrals as cancer numbers remain stable
FierceBiotech 4. Feb. 2026 Novo's CEO 'wishes Pfizer luck' with Metsera drug, but still seeks own monthly GLP-1
FierceBiotech 4. Feb. 2026 Amgen advances toward lupus redemption while gastric cancer candidate struggles
FierceBiotech 4. Feb. 2026 NIH turmoil takes center stage as director acknowledges no vaccine-autism link
FierceBiotech 3. Feb. 2026 Pfizer CEO says pipeline pruning is mostly finished after 6 more early-stage culls, $4.4B in impairment charges
FierceBiotech 3. Feb. 2026 Fledgling biotech Exxel plans $13M IPO to succeed where other FAAH inhibitors have failed
FierceBiotech 3. Feb. 2026 FDA signals tailored approach to ‘carefully shepherd’ CAR-T therapy for autoimmune diseases
FierceBiotech 3. Feb. 2026 Pfizer's $10B monthly GLP-1 bet generates competitive weight loss in phase 2b
FierceBiotech 3. Feb. 2026 NMD flunks rare disease trial but flexes secondary data to accelerate program